Israel Begins Exporting Cannabis to the UK

A new era of medical cannabis exports is underway in Israel after a Revadim-based firm sent a shipment to the UK.

It is precisely one year since the Israeli government approved cannabis exports, but licenses have been held up in red tape. At one point the government was even pledging to expedite applications for producers that fell in line with new domestic regulations requiring them to sell marijuana via pharmacies rather than direct to consumer.

BOL Pharma, a cultivator based in the kibbutz of Revadim in the south of Israel, said it has received a license and sent its first batch to Britain. It is destined for centres that specialize in the treatment of children with epilepsy and autism.

BOL Pharma chief executive Dr. Tamir Gedo called it “a real breakthrough” for the Israeli medical cannabis market. He said that Israel has a huge competitive edge over rivals in the emerging sector and added: “Further opening of the market to exports will enable Israel to become a world leader in the coming years.”

Israel has a long history as a pioneer within the field of medical cannabis. In Novemeber 2019, government mapped out ambitious plans to grow the country’s medical cannabis sector in a new white paper aimed at overseas investors.

However, the volume of production remains relatively modest. The government feared exports would lead to an increase in production, which would cause an overspill that increased the country’s black market.

Producers threatened to up sticks and move to Europe if the government did not relent, so it eventually legalized exports. Israel is well placed geographically to serve the European cannabis market, which is tipped to become the largest in the world within a few years.

Subscribe Now
Sign up to get Grizzle's latest news and analysis in your inbox!

Sending Message...

The UK has the potential to develop into one of the largest markets in the world, due to the size and affluence of its population. It legalized medical cannabis in November 2018, but the first products are only just starting to be approved for NHS prescriptions.

Campaigners have spent the past 14 months calling for better patient access and they may be cheered to learn of BOL Pharma’s export deal.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Subscribe Now
Sign up to get Grizzle's latest news and analysis in your inbox!

Sending Message...

Categories: Marijuana Politics
Martin Green: Martin Green is an experienced journalist with a strong focus on the cannabis, alcohol, and gambling industries. He is particularly interested in the political issues affecting the global marijuana trade, and he has a keen focus on regulation changes and legal topics. He holds a BA English Literature, MA Creative Writing and a National Qualification in Journalism diploma. He has worked in journalism since 2009 and written for a broad range of newspapers, business titles and magazines, including The Sun, The Metro, The Journal, Livestrong, Drinks Retailing News, Harpers, Sportsbook Review, Vital Football, Essex Live and Surrey Live.
Related Post
Disqus Comments Loading...